8:00 am Check-In & Coffee
8:50 am Chair’s Opening Remarks
Clarifying Regulators Expectations & Criteria to Accelerate IND Approvals to Drive Pipelines Forward
9:00 am Focusing on Regulatory Obstacles Which Could Potentially Limit Translation into the Clinic
Synopsis
- Understanding the criteria set for applications to be approved to move forward into the clinic
- Looking into case studies and experiences of therapies currently in the clinic to gain insights into negotiations with regulatory bodies
- Planning for future applications to gain approval first time
Showcasing Groundbreaking Preclinical & Clinical Data in Various Indications
9:30 am Exploring New Data & Addressing Challenges in Treating Parkinson’s Disease (PD) Using Cell Therapies
Synopsis
- Discussing different origins of PD (idiopathic/genetic causes) to understand the scope of the disease
- Considering which forms of PD would be most suited to being treated with cell therapies
- Presenting promising data showing improved outcomes for patients with PD treated with cell therapies
10:00 am Driving Pipelines for Alzheimer’s Disease (AD) & Parkinson’s Disease (PD): Unleashing the Potential of NK Cell Therapies for Neurodegenerative Diseases
Synopsis
- Navigating the need novel cell therapies in comparison to other forms of treatment for AD and PD
- Exploring the newest NK cell therapy data in AD to reveal positive results discovered thus far
- Planning for the future of NK cell therapies in neurodegenerative diseases to suggest directions for these indications
10:30 am Morning Break & Networking
11:00 am Discussing Progress & Newest Data in Cell Therapies Treating Epilepsy to Showcase Promise for Patients
Synopsis
- Development of a pluripotent stem cell-derived cell therapy product for the treatment of focal epilepsy
- Evaluation in preclinical animal models
- Emerging clinical data from ongoing clinical trials
- Understanding challenges in the democratization of cell therapies for CNS
11:30 am Coya 302: A Dual Mechanism Potential Biological Immunotherapy for ALS and FTD
Synopsis
- Treg dysfunction as a core driver of neurodegeneration in ALS and FTD
- Coya 302 targets adaptive and innate immune pathways
- Coya 302 as potential therapy for ALS and FTD
12:00 pm CAR-T: The next frontier in Multiple Sclerosis & other Demyelinating Diseases
Synopsis
- Science behind CAR-T in Autoimmune Neurological Diseases
- Clinical data so far in CNS Demyelinating Diseases
- What the future holds
12:30 pm Lunch Break & Networking
1:30 pm Delving into Cell Therapy for Spinal Cord Injury (SCI)
Synopsis
- Navigating data showing the potential of cell therapies in SCI to highlight the scope of treatment
- Learning about the forms of SCI that cell therapies are involved in treating
- Considering which types of SCI cell therapies could treat in the future
2:00 pm Panel Discussion: Choosing Targets in Diseases with Multiple Causes & Affected Areas & Considering Accessibility
Synopsis
- Deciding on what criteria (market gap, potential etc) should be used to select treatment area
- Unravelling the challenges in developing therapeutics for disorders with a wide variety of potential origins
- Discussing patient perspective and accessibility for treatments
2:30 pm Afternoon Break & Networking
Rationalizing Target Indications & Discussing Motivations Behind Developing Cell Therapies for Specific Indications
3:00 pm Examining Future Potential Indications of Cell Therapies for Neurological Disorders
Synopsis
- Discovering the next potential neurological indications where cell therapies could be utilized in neurological disorders such as pain, autism, etc
- Reviewing the literature to understand how efficacious cell therapies could be in these areas
- Unravelling the challenges associated with these different indications
3:30 pm Panel Discussion: Exploring the ‘Low Hanging Fruit’ Indications & Choosing Specific Target Indications
Synopsis
- Which indications are expected to be the first to accelerate through the clinic?
- Which indications have the most funding associated with them?